AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
Go back to AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042| ALLIANCEBERNSTEIN HOLDING, L.P. (NYSE: AB) | Delayed: 35.99 -0.12 (0.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.11 | 52 Week High | $26.24 | |||
| Open | $35.76 | 52 Week Low | $16.11 | |||
| Day High | $36.00 | P/E | 21.17 | |||
| Day Low | $35.69 | EPS | $1.70 | |||
| Volume | 67,898 | |||||
